Zogenix, Inc. (NASDAQ:ZGNX) – Piper Jaffray Companies issued their Q3 2018 earnings estimates for shares of Zogenix in a report released on Monday, November 5th. Piper Jaffray Companies analyst D. Brill expects that the company will post earnings of ($0.82) per share for the quarter. Piper Jaffray Companies currently has a “Overweight” rating on the stock. Piper Jaffray Companies also issued estimates for Zogenix’s Q4 2018 earnings at ($0.94) EPS, FY2018 earnings at ($3.46) EPS, Q1 2019 earnings at ($0.80) EPS, Q2 2019 earnings at ($0.89) EPS, Q3 2019 earnings at ($0.71) EPS, Q4 2019 earnings at ($0.76) EPS, FY2019 earnings at ($3.18) EPS, FY2020 earnings at ($0.11) EPS, FY2021 earnings at $4.33 EPS and FY2022 earnings at $6.54 EPS.
Other equities analysts also recently issued reports about the company. Leerink Swann reaffirmed an “outperform” rating on shares of Zogenix in a research note on Friday, October 19th. Stifel Nicolaus started coverage on Zogenix in a report on Wednesday, August 15th. They set a “buy” rating and a $69.00 target price on the stock. Mizuho reiterated a “buy” rating and set a $69.00 target price on shares of Zogenix in a report on Thursday, August 9th. LADENBURG THALM/SH SH started coverage on Zogenix in a report on Thursday, August 23rd. They set a “buy” rating and a $71.00 target price on the stock. Finally, BidaskClub cut Zogenix from a “hold” rating to a “sell” rating in a report on Friday, August 17th. One investment analyst has rated the stock with a hold rating and twelve have given a buy rating to the stock. Zogenix presently has a consensus rating of “Buy” and an average target price of $71.90.
NASDAQ ZGNX opened at $42.18 on Wednesday. Zogenix has a 1-year low of $32.40 and a 1-year high of $62.75. The company has a market capitalization of $1.57 billion, a P/E ratio of -10.49 and a beta of 1.86.
Zogenix (NASDAQ:ZGNX) last released its quarterly earnings data on Monday, August 6th. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.06. During the same period in the previous year, the company earned ($0.90) earnings per share.
In other Zogenix news, major shareholder Life Sciences Maste Perceptive acquired 100,000 shares of the firm’s stock in a transaction dated Friday, August 10th. The shares were acquired at an average price of $52.00 per share, for a total transaction of $5,200,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Gail M. Farfel sold 7,000 shares of the firm’s stock in a transaction on Tuesday, September 4th. The stock was sold at an average price of $47.58, for a total value of $333,060.00. The disclosure for this sale can be found here. 4.60% of the stock is currently owned by corporate insiders.
Several hedge funds have recently bought and sold shares of ZGNX. BlueMountain Capital Management LLC acquired a new stake in shares of Zogenix during the second quarter worth $104,000. SG Americas Securities LLC acquired a new stake in shares of Zogenix during the third quarter worth $109,000. FNY Investment Advisers LLC boosted its holdings in shares of Zogenix by 3,900.0% during the third quarter. FNY Investment Advisers LLC now owns 3,000 shares of the company’s stock worth $148,000 after purchasing an additional 2,925 shares during the last quarter. Public Employees Retirement Association of Colorado acquired a new stake in shares of Zogenix during the third quarter worth $226,000. Finally, Amalgamated Bank acquired a new stake in shares of Zogenix during the second quarter worth $232,000.
Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome.
Further Reading: Cost of Capital
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.